Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans

Dong Jik Shin, Jisun Kwon, Ah Ram Park, Yousun Bae, Eun Soon Shin, Sungha Park, Yangsoo Jang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: The cytochrome P450 2C19 (CYP2C19) metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure. Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. The aim of the present study was to evaluate the association between two variants, CYP2C19* 2 (681G>A) and CYP2C19*3 (636G>A) and the development of essential hypertension (EH) in Koreans. Materials and Methods: We carried out an association study in a total of 1190 individuals (527 hypertensive subjects and 663 unrelated healthy controls). The CYP2C19 polymorphisms were genotyped using the SNaPShotTM assay. Results: The distribution of alleles and genotypes of CYP2C19* 3 showed significant difference between hypertensive patients and normal controls (p=0.011 and p=0.013, respectively). Logistic regression analysis indicated that the CYP2C19*3 (636A) allele carriers were significantly associated with EH [odds ratio, 0.691; 95% confidence interval (CI), 0.512-0.932, p=0.016], in comparison to wild type homozygotes (CYP2C19*1/*1). Neither genotype nor allele distribution of CYP2C19*2 polymorphism showed significant differences between hypertensive and control groups (p>0.05). Conclusion: Our present findings strengthen the evidence of an association between CYP2C19 gene polymorphism and EH prevalence. In particular, the CYP2C19*3 defective allele may contribute to reduced risk for the development of EH.

Original languageEnglish
Pages (from-to)1113-1119
Number of pages7
JournalYonsei medical journal
Volume53
Issue number6
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Cytochrome P-450 Enzyme System
Alleles
Essential Hypertension
Genotype
Genes
Homozygote
Arachidonic Acid
Blood Vessels
Cardiovascular Diseases
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Blood Pressure
Control Groups
Acids

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Shin, Dong Jik ; Kwon, Jisun ; Park, Ah Ram ; Bae, Yousun ; Shin, Eun Soon ; Park, Sungha ; Jang, Yangsoo. / Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans. In: Yonsei medical journal. 2012 ; Vol. 53, No. 6. pp. 1113-1119.
@article{00d4957899514af7b54c9aa082889c71,
title = "Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans",
abstract = "Purpose: The cytochrome P450 2C19 (CYP2C19) metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure. Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. The aim of the present study was to evaluate the association between two variants, CYP2C19* 2 (681G>A) and CYP2C19*3 (636G>A) and the development of essential hypertension (EH) in Koreans. Materials and Methods: We carried out an association study in a total of 1190 individuals (527 hypertensive subjects and 663 unrelated healthy controls). The CYP2C19 polymorphisms were genotyped using the SNaPShotTM assay. Results: The distribution of alleles and genotypes of CYP2C19* 3 showed significant difference between hypertensive patients and normal controls (p=0.011 and p=0.013, respectively). Logistic regression analysis indicated that the CYP2C19*3 (636A) allele carriers were significantly associated with EH [odds ratio, 0.691; 95{\%} confidence interval (CI), 0.512-0.932, p=0.016], in comparison to wild type homozygotes (CYP2C19*1/*1). Neither genotype nor allele distribution of CYP2C19*2 polymorphism showed significant differences between hypertensive and control groups (p>0.05). Conclusion: Our present findings strengthen the evidence of an association between CYP2C19 gene polymorphism and EH prevalence. In particular, the CYP2C19*3 defective allele may contribute to reduced risk for the development of EH.",
author = "Shin, {Dong Jik} and Jisun Kwon and Park, {Ah Ram} and Yousun Bae and Shin, {Eun Soon} and Sungha Park and Yangsoo Jang",
year = "2012",
month = "11",
day = "1",
doi = "10.3349/ymj.2012.53.6.1113",
language = "English",
volume = "53",
pages = "1113--1119",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans. / Shin, Dong Jik; Kwon, Jisun; Park, Ah Ram; Bae, Yousun; Shin, Eun Soon; Park, Sungha; Jang, Yangsoo.

In: Yonsei medical journal, Vol. 53, No. 6, 01.11.2012, p. 1113-1119.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans

AU - Shin, Dong Jik

AU - Kwon, Jisun

AU - Park, Ah Ram

AU - Bae, Yousun

AU - Shin, Eun Soon

AU - Park, Sungha

AU - Jang, Yangsoo

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose: The cytochrome P450 2C19 (CYP2C19) metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure. Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. The aim of the present study was to evaluate the association between two variants, CYP2C19* 2 (681G>A) and CYP2C19*3 (636G>A) and the development of essential hypertension (EH) in Koreans. Materials and Methods: We carried out an association study in a total of 1190 individuals (527 hypertensive subjects and 663 unrelated healthy controls). The CYP2C19 polymorphisms were genotyped using the SNaPShotTM assay. Results: The distribution of alleles and genotypes of CYP2C19* 3 showed significant difference between hypertensive patients and normal controls (p=0.011 and p=0.013, respectively). Logistic regression analysis indicated that the CYP2C19*3 (636A) allele carriers were significantly associated with EH [odds ratio, 0.691; 95% confidence interval (CI), 0.512-0.932, p=0.016], in comparison to wild type homozygotes (CYP2C19*1/*1). Neither genotype nor allele distribution of CYP2C19*2 polymorphism showed significant differences between hypertensive and control groups (p>0.05). Conclusion: Our present findings strengthen the evidence of an association between CYP2C19 gene polymorphism and EH prevalence. In particular, the CYP2C19*3 defective allele may contribute to reduced risk for the development of EH.

AB - Purpose: The cytochrome P450 2C19 (CYP2C19) metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure. Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. The aim of the present study was to evaluate the association between two variants, CYP2C19* 2 (681G>A) and CYP2C19*3 (636G>A) and the development of essential hypertension (EH) in Koreans. Materials and Methods: We carried out an association study in a total of 1190 individuals (527 hypertensive subjects and 663 unrelated healthy controls). The CYP2C19 polymorphisms were genotyped using the SNaPShotTM assay. Results: The distribution of alleles and genotypes of CYP2C19* 3 showed significant difference between hypertensive patients and normal controls (p=0.011 and p=0.013, respectively). Logistic regression analysis indicated that the CYP2C19*3 (636A) allele carriers were significantly associated with EH [odds ratio, 0.691; 95% confidence interval (CI), 0.512-0.932, p=0.016], in comparison to wild type homozygotes (CYP2C19*1/*1). Neither genotype nor allele distribution of CYP2C19*2 polymorphism showed significant differences between hypertensive and control groups (p>0.05). Conclusion: Our present findings strengthen the evidence of an association between CYP2C19 gene polymorphism and EH prevalence. In particular, the CYP2C19*3 defective allele may contribute to reduced risk for the development of EH.

UR - http://www.scopus.com/inward/record.url?scp=84868135101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868135101&partnerID=8YFLogxK

U2 - 10.3349/ymj.2012.53.6.1113

DO - 10.3349/ymj.2012.53.6.1113

M3 - Article

C2 - 23074110

AN - SCOPUS:84868135101

VL - 53

SP - 1113

EP - 1119

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -